# OnCo record diffusion-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/diffusion-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "diffusion-pharmaceuticals" ;
  schema:name "Diffusion Pharmaceuticals"@en ;
  schema:alternateName "Diffusion Pharmaceuticals Inc"@en, "Diffusion Pharmaceuticals LLC"@en ;
  schema:description "Diffusion developed trans sodium crocetinate, a small molecule meant to carry more oxygen into tumours so radiotherapy works better; its phase 3 trial in glioblastoma was cut short and the company merged into another biotech in 2023."@en ;
  schema:url <https://onco.cc/companies/diffusion-pharmaceuticals/>, <http://www.diffusionpharma.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Diffusion_Pharmaceuticals> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5275432> ;
  schema:citation <http://www.diffusionpharma.com>, <https://clinicaltrials.gov/search?lead=Diffusion%20Pharmaceuticals%20Inc>, <https://www.wikidata.org/wiki/Q5275432> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/radiation/> ;
  onco:technologies <https://onco.cc/technologies/radiosensitisers/>, <https://onco.cc/technologies/tumour-hypoxia-modification/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> .